|
1
|
Llorens MA, Bermejo MJ, Salcedo MC, Charro
AL and Puente M: Epidermal growth factor receptors in human breast
and endometrial carcinomas. J Steroid Biochem. 34:505–509. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Niikura H, Sasano H, Kaga K, Sato S and
Yajima A: Expression of epidermal growth factor family proteins and
epidermal growth factor receptor in human endometrium. Hum Pathol.
27:282–289. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Houston KD, Copland JA, Broaddus RR,
Gottardis MM, Fischer SM and Walker CL: Inhibition of proliferation
and estrogen receptor signaling by peroxisome
proliferator-activated receptor gamma ligands in uterine leiomyoma.
Cancer Res. 63:1221–1227. 2003.PubMed/NCBI
|
|
4
|
Braissant O, Foufelle E, Scotto C, Dauça M
and Wahli W: Differential expression of peroxisome
proliferator-activated receptors (PPARs): Tissue distribution of
PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology.
137:354–366. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhao Y, Tan YS, Strynar MJ, Perez G,
Haslam SZ and Yang C: Perfluorooctanoic acid effects on ovaries
mediate its inhibition of peripubertal mammary gland development in
Balb/c and C57Bl/6 mice. Reprod Toxicol. 33:563–576. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mitchell DC and Ing NH: Estradiol
stabilizes estrogen receptor messenger ribonucleic acid in sheep
endometrium via discrete sequence elements in its 3′-untranslated
region. Mol Endocrinol. 17:562–574. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bonofiglio D, Gabriele S, Aquila S,
Catalano S, Gentile M, Middea E, Giordano F and Andó S: Estrogen
receptor alpha binds to peroxisome proliferator-activated receptor
response element and negatively interferes with peroxisome
proliferator-activated receptor gamma signaling in breast cancer
cells. Clin Cancer Res. 11:6139–6147. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mu YM, Yanase T, Nishi Y, Takayanagi R,
Goto K and Nawata H: Combined treatment with specific ligands for
PPARgamma: RXR nuclear receptor system markedly inhibits the
expression of cytochrome P450arom in human granulosa cancer cells.
Mol Cell Endocrinol. 181:239–248. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang QH, Han N, Dai N, Wang X and Ao W:
Anti-inflammatory effects and structure elucidation of two new
compounds from Astragalus membranaceus (Fisch) Bge. var.
mongholicus (Bge) Hsiao. J Mol Struc. 1074:284–288. 2014.
View Article : Google Scholar
|
|
10
|
No authors listed: Astragalus
membranaceus. Monograph. Altern Med Rev. 8:72–77. 2003.PubMed/NCBI
|
|
11
|
Chen J, Ge B, Wang Y, Ye Y, Zeng S and
Huang Z: Biochanin A promotes proliferation that involves a
feedback loop of microRNA-375 and estrogen receptor alpha in breast
cancer cells. Cell Physiol Biochem. 35:639–646. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tohda C, Tamura T, Matsuyama S and Komatsu
K: Promotion of axonal maturation and prevention of memory loss in
mice by extracts of Astragalus mongholicus. Br J Pharmacol.
149:532–541. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kitagawa I, Wang HK, Saito M, Takagi A and
Yoshikawa M: Saponin and sapogenol. XXXV. Chemical constituents of
Astragali radix, the root of Astragalus membranaceus BUNGE. (2).
Astragalosides I, II and IV, Acetylastragaloside I and
isoastragalosides I and II. Chem Pharm Bull. 31:698–708. 1983.
View Article : Google Scholar
|
|
14
|
Luo HL, Zhong J, Ye FY, Wang Q, Ma YM, Liu
P, Zhang H, Sunc MY and Jiang J: A systematic quality control
method of Huangqi decoction: Simultaneous determination of eleven
flavonoids and seven triterpenoid saponins by UHPLC-MS. Anal
Methods. 6:4593–4601. 2014. View Article : Google Scholar
|
|
15
|
Wang X, Wang Y, Hu JP, Yu S, Li BK, Cui Y,
Ren L and Zhang LD: Astragaloside IV, a natural PPARγ agonist,
reduces Aβ production in Alzheimer's disease through inhibition of
BACE1. Mol Neurobiol. 54:2939–2949. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jiang K, Lu Q, Li Q, Ji Y, Chen W and Xue
X: Astragaloside IV inhibits breast cancer cell invasion by
suppressing Vav3 mediated Rac1/MAPK signaling. Int Immunopharmacol.
42:195–202. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang PP, Xu DJ, Huang C, Wang WP and Xu
WK: Astragaloside IV reduces the expression level of P-glycoprotein
in multidrug-resistant human hepatic cancer cell lines. Mol Med
Rep. 9:2131–2137. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cheng X, Gu J, Zang M, Yuan J, Zhao B,
Jiang J and Jia X: Astragaloside IV inhibits migration and invasion
in human lung cancer A549 cells via regulating PKC-α-ERK1/2-NF-κB
pathway. Int Immunopharmacol. 23:304–313. 2010. View Article : Google Scholar
|
|
19
|
Kobayashi K, Matsuyama W, Arai Y, Koizumi
S, Shimizu T, Tomioka R and Sasaki K: Boiogito increases the
metabolism of fatty acids in proximal tubular cells through
peroxisome proliferators-activated receptor (PPAR) α agonistic
activity. Biol Pharm Bull. 39:143–147. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCt method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dommes V, Baumgart C and Kunau WH:
Degradation of unsaturated fatty acids in peroxisomes. Existence of
a 2,4-dienoyl-CoA reductase pathway. J Biol Chem. 256:8259–8262.
1981.PubMed/NCBI
|
|
22
|
Hakkola EH, Autio-Harmainen HI, Sormunen
RT, Hassinen IE and Hiltunen JK: The known purified mammalian
2,4-dienoyl-CoA reductases are mitochondrial isoenzymes. J
Histochem Cytochem. 37:1863–1867. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rak-Mardyła A and Drwal E: In vitro
interaction between resistin and peroxisome proliferator-activated
receptor γ in porcine ovarian follicles. Reprod Fertil Dev.
28:357–368. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Willson TM, Brown PJ, Sternbach DD and
Henke BR: The PPARs: From orphan receptors to drug discovery. J Med
Chem. 43:527–550. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang T, Zhang M, Jiang Z and Seli E:
Mitochondrial dysfunction and ovarian aging. Am J Reprod Immunol.
77:e126512017. View Article : Google Scholar
|
|
26
|
Keller H, Givel F, Perroud M and Wahli W:
Signaling cross-talk between peroxisome proliferator-activated
receptor/retinoid X receptor and estrogen receptor through estrogen
response elements. Mol Endocrinol. 9:794–804. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dassen H, Punyadeera C, Delvoux B,
Schulkens I, Marchetti C, Kamps R, Klomp J, Dijcks F, de Goeij A,
D'Hooghe T, et al: Olfactomedin-4 regulation by estrogen in the
human endometrium requires epidermal growth factor signaling. Am J
Pathol. 177:2495–2508. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gunin AG, Bitter AD, Demakov AB, Vasilieva
EN and Suslonova NV: Effects of peroxisome proliferator activated
receptors-alpha and -gamma agonists on estradiol-induced
proliferation and hyperplasia formation in the mouse uterus. J
Endocrinol. 182:229–239. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kurman RJ, Kaminski PF and Norris HJ: The
behavior of endometrial hyperplasia. A long-term study of
‘untreated’ hyperplasia in 170 patients. Cancer. 56:403–412. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lindahl B and Willén R: Spontaneous
endometrial hyperplasia. A prospective, 5 year follow-up of 246
patients after abrasio only, including 380 patients followed-up for
2 years. Anticancer Res. 14:2141–2146. 1994.PubMed/NCBI
|
|
31
|
Truman AM, Tilly JL and Woods DC: Ovarian
regeneration: The potential for stem cell contribution in the
postnatal ovary to sustained endocrine function. Mol and Cell
Endocrinol. 445:74–84. 2017. View Article : Google Scholar
|
|
32
|
Erler P, Sweeney A and Monaghan JR:
Regulation of injury-induced ovarian regeneration by activation of
Oogonial stem cells. Stem Cells. 35:236–247. 2017. View Article : Google Scholar : PubMed/NCBI
|
